Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

BCC 2025 | Challenges in precision medicine in early-breast cancer

Tanja Spanic • 13 Mar 2025
BCC 2025
Breast Cancer

Tanja Spanic, PhD, Europa Donna Slovenia, Ljubljana, Slovenia, comments on the recent evolution of cancer therapies and current challenges in precision medicine in early breast-cancer. Educating patients to understand the benefits and risks of treatments is critical to tackling these challenges. This interview took place at the 2025 St. Gallen International Breast Cancer Consensus Meeting in Vienna, Austria.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Tanja Spanic

Maintaining patient trust in precision medicine for breast cancer
0:32
Maintaining patient trust in precision medicine for breast cancer
Tanja Spanic • 13 Mar 2025
Incorporating patient perspectives into breast cancer trial design
1:12
Incorporating patient perspectives into breast cancer trial design
Tanja Spanic • 13 Mar 2025
The importance of survivorship in patients with breast cancer
0:56
The importance of survivorship in patients with breast cancer
Tanja Spanic • 13 Mar 2025
De-escalating treatment of patients with breast cancer
1:31
De-escalating treatment of patients with breast cancer
Tanja Spanic • 17 Mar 2023

Related Videos

Phase I trial of neoadjuvant rintatolimod and celecoxib in resectable mCRC
1:20
Phase I trial of neoadjuvant rintatolimod and celecoxib in resectable mCRC
Sarbajit Mukherjee • 1 Jun 2026
CRCI and compromised adjuvant chemotherapy delivery in cancer
5:16
CRCI and compromised adjuvant chemotherapy delivery in cancer
Filippos Koinis • 1 Jun 2026
ASCENT-04: PFS2 with sacituzumab govitecan and pembrolizumab in PD-L1+ mTNBC
1:12
ASCENT-04: PFS2 with sacituzumab govitecan and pembrolizumab in PD-L1+ mTNBC
Kevin Kalinsky • 31 May 2026
Clinical relevance of PFS2 in metastatic triple-negative breast cancer
1:10
Clinical relevance of PFS2 in metastatic triple-negative breast cancer
Kevin Kalinsky • 31 May 2026
The content of VJOncology is intended for healthcare professionals